Inhibition of CD36 in cancer immunotherapy

Depleting regulatory T cells (Treg cells) to counteract immunosuppressive features of the tumor microenvironment (TME) is an attractive strategy for cancer treatment. The latest study of CD36 proteins was published in Nature immunology. The publication showed that genetic ablation of CD36 in Treg cells suppressed tumor growth. Furthermore, CD36 targeting elicited additive antitumor responses with anti-PD-1 therapy.

To help the drug development, ACRO has developed high-quality CD36 protein and bioactivity was verified.

※ Cover all common Fc receptor molecules including their variants with different species and tags

※ Bioactivity was verified by SPR and protocols are offered for free.

Human CD36, His Tag (Cat. No. CD6-H5221) immobilized on CM5 Chip can bind Human Thrombospondin-2, His Tag (Cat. No. TH2-H52H5) with an affinity constant of 21 nM as determined in a SPR assay (Biacore 8K). Request Free Protocol >>

Product List